Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Operating Expenses of $10.0 million for Q1 2026, up 961.47% year-over-year from $945381.8 in Q1 2025, and up 1462.66% quarter-over-quarter from $642169.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Operating Expenses for 4 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 961.47% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $17.4 million (up 1595.49% YoY), while the FY2025 annual figure was -$1.4 million, changed N/A from the prior year.
- Other Operating Expenses rose to $10.0 million in Q1 2026 per IKT's latest filing, from $642169.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $10.0 million in Q1 2026 and bottomed at -$10.6 million in Q4 2023.
- Historically, Other Operating Expenses has averaged $945029.0 across 3 years, with a median of $141874.5 in 2025.
- On a YoY basis, Other Operating Expenses climbed as much as 961.47% in 2026 and fell as far as 961.47% in 2026.
- Inhibikase Therapeutics' Other Operating Expenses stood at -$10.6 million in 2023, then soared by 106.07% to $642169.0 in 2025, then surged by 1462.66% to $10.0 million in 2026.
- Business Quant data shows IKT's Other Operating Expenses at $10.0 million in Q1 2026, $642169.0 in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.03 Mn |
| Dec 31, 2025 | 642,169.00 |
| Sep 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | -358,420.00 |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2023 | -10.59 Mn |
| Dec 31, 2020 | 1.94 Mn |